KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Operations: 2009-2024

Historic Cash from Operations for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $1.4 billion.

  • Jazz Pharmaceuticals' Cash from Operations rose 19.03% to $474.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 19.50%. This contributed to the annual value of $1.4 billion for FY2024, which is 27.83% up from last year.
  • According to the latest figures from FY2024, Jazz Pharmaceuticals' Cash from Operations is $1.4 billion, which was up 27.83% from $1.1 billion recorded in FY2023.
  • In the past 5 years, Jazz Pharmaceuticals' Cash from Operations ranged from a high of $1.4 billion in FY2024 and a low of $778.5 million during FY2021.
  • For the 3-year period, Jazz Pharmaceuticals' Cash from Operations averaged around $1.3 billion, with its median value being $1.3 billion (2022).
  • Per our database at Business Quant, Jazz Pharmaceuticals' Cash from Operations skyrocketed by 63.39% in 2022 and then fell by 14.15% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Cash from Operations (Yearly) stood at $899.6 million in 2020, then dropped by 13.47% to $778.5 million in 2021, then surged by 63.39% to $1.3 billion in 2022, then dropped by 14.15% to $1.1 billion in 2023, then rose by 27.83% to $1.4 billion in 2024.